RxDoctor Payments Data

Carmi Punzalan, MD

Gastroenterology · Burlington, MANPI 1053584037

Payments from drug & device makers

$12,488in general payments, 2019–2025

Across 27 payments — averaging $462.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$8K
  • Ipsen Biopharmaceuticals, Inc$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$37
  • AstraZeneca$29
  • Veloxis Pharmaceuticals, Inc.$6

What the payments were for

  • Consulting fees$5,12041%
  • Speaking & faculty fees$5,96948%
  • Travel & lodging$2662%
  • Food & beverage$1,1339%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,488 in reported general payments places this provider in the 75th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$71,220
Medicare patients
263
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin144$509,598
OcalivaObeticholic Acid16$152,922
RezdiffraResmetirom18$96,062
VemlidyTenofovir Alafenamide35$61,638
Tacrolimus137$28,983
Ursodiol174$26,468
Entecavir14$10,057
Mycophenolate Mofetil67$5,659
Cyclosporine ModifiedCyclosporine, Modified20$3,748
Lactulose68$3,714
Azathioprine43$2,235
Carvedilol135$977
Spironolactone108$947
Lamivudine HbvLamivudine12$612
Nadolol21$392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,250$509,598144 claims
Madrigal PharmaceuticalsRezdiffra$8,184$96,06218 claims
GileadVemlidy$37$61,63835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →